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The aim of this study was to trace D-amphetamine toxicity in isolated rat hepatocytes and to elucidate 
a possible involvement of CYP3A in the mechanisms of its toxicity. To this end, male Wistar rats were 
treated with nifedipine (5 mg kg-1 i.p., 5 days), a substrate and inducer of CYP3A. Hepatocytes isolated from 
nifedipine-treated and control rats were incubated with D-amphetamine at a concentration of 100 µmol L-1, 
which was determined to be an average toxic concentration (TC
50
) for the compound. To evaluate the 
possible toxic effects of D-amphetamine on freshly isolated rat hepatocytes, we assessed the following 
parameters: cell viability, lactate dehydrogenase (LDH) activity, and glutathione (GSH).
The results showed that nifedipine potentiated amphetamine cytotoxicity in vitro, as follows: cell viability 
dropped by 65 % (p<0.001), GSH by 80 % (p<0.001), and LDH activity increased by 190 % (p<0.001).
To clarify the role of nifedipine in amphetamine cytotoxicity, we used amiodarone, a substrate and an 
inhibitor of CYP3A. Pre-incubation of nifedipine-treated hepatocytes with amiodarone (14 µmol L-1) 
signifi cantly lowered amphetamine cytotoxicity.
Our results confi rmed the toxicity of D-amphetamine in isolated rat hepatocytes and the involvement of 
CYP3A in its metabolism and hepatotoxicity.
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Amphetamines are potent psychostimulants and 
commonly used drugs of abuse. Not only does chronic 
amphetamine administration create tolerance and 
addiction, but is also associated with neurotoxicity 
and hepatocellular damage through oxidative stress. 
Amphetamine is a drug of abuse with variable 
interspecies biotransformation (1). In rats its aromatic 
ring is hydroxylated, and the urinary excretion of p-
hydroxyamphetamine (81 %) is the main elimination 
pathway (1). Animal studies in vitro (2) and in vivo 
(3) have proved that D-amphetamine 4-hydroxylation 
in rats is favoured by CYP2D. This metabolic 
pathway is thought to be responsible for amphetamine 
hepatotoxicity. Experimental studies performed in 
isolated rat hepatocytes by Carvalho et al. (4) have 
proved that in the liver D-amphetamine metabolises 
into an epoxide, its toxic intermediate, which reacts 
with glutathione, and forms a GSH-adduct (GSH-
S-yl-p-hydroxyamphetamine). This partly explains 
D-amphetamine hepatotoxicity. D-amphetamine 
is a substrate of CYP2D, but it is also known to 
inhibit cytochrome P450 through a nitroso metabolic 
intermediate, which complexes with the enzyme and 
causes its inhibition and possible toxic effects (5, 6). 
The main cytochrome P450 isoform which catalyses 
the formation of the nitroso intermediate is CYP3A 
(7).
This suggests a possible involvement of other 
cytochrome P450 isoenzymes in D-amphetamine 
metabolism and hepatotoxicity, and the objective of 
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Male Wistar rats (body weight 200 g to 250 
g) were housed in Plexiglas cages (3 per cage) at 
(20±2) °C and 12-h light : 12-h dark cycle. Food 
and water were provided ad libitum. The animals 
were purchased from the National Breeding Centre, 
Sofi a, Bulgaria. All procedures were approved by the 
Institutional Animal Care Committee and performed 
strictly following the principles stated in the European 
Convention for the Protection of Vertebrate Animals 
used for Experimental and other Scientifi c Purposes 
(ETS 123) (1991) (8).
Experimental design
The animals were divided in two groups (n=6): the 
control group treated intraperitoneally (i.p.) with saline 
0.9 % twice a day for 5 days, and a group receiving 
intraperitonally 5 mg kg-1 of nifedipine, an inducer 
of CYP 3A, twice a day for 5 days. This nifedipine 
dose was based on previous experiments in which 
we found that multiple nifedipine administration to 
rats (5 mg kg-1, i.p., twice daily for 5 days) led to an 
increase in cytochrome P450 (9).
Chemicals and reagents
All reagents used were of analytical grade. The 
drugs used in this study, D-amphetamine sulphate, 
nifedipine, and amiodarone, as well as other chemicals, 
collagenase (type IV), bovine serum albumin (fraction 
V), 4-(2-hydroxyethyl)-1-piper-azineethanesulphonic 
acid (HEPES), glutathione (GSH), and [ethylenebis
(oxyethylenenitrilo)] tetraacetic acid (EGTA) were 
purchased form Sigma Chemical Co. (Germany). 
2,2’-dinitro-5,5’dithiodibenzoic acid (DTNB) was 
obtained from MERCK (Germany) and the Lactate 
Dehydrogenase Kit (EC 1.1.1.27) was obtained from 
Randox (United Kingdom).
Isolation of hepatocytes
Rats were anesthetised with sodium pentobarbutal 
(0.2 mL per 100 g b. w.).Two-stepped collagenase 
liver perfusion and cell isolation were performed 
in situ, as described by Fau (10) with modifi cations 
(11). After portal catheterisation, the liver was 
perfused with 100 mL of HEPES buffer (pH=7.85) 
containing 10 mmol L-1 HEPES, 142 mmol L-1 NaCl, 
7 mmol L-1 KCl, 5 mmol L-1 glucose, and 0.6 mmol L-1 
EDTA (pH=7.85), then by 200 mL of HEPES buffer 
(pH=7.85) alone, and fi nally by 200 mL of HEPES 
buffer containing collagenase type IV (50 mg per 
200 mL) and 7 mmol L-1 CaCl
2
 (pH = 7.85). The 
liver was removed, minced, and hepatocytes were 
dispersed in 60 mL Krebs-Ringer-bicarbonate (KRB) 





1 mmol L-1 CaCl
2
, 1.2 mmol L-1 MgSO
4
, 5 mmol L-1 
KCl, 5 mmol L-1 NaHCO
3
, 4.5 mmol L-1 glucose, 
and 1 % bovine serum albumin. After fi ltration, the 
hepatocytes were centrifuged at 500xg for 1 min and 
washed three times with the KRB buffer. The initial 
viability, assessed using the Trypan blue exclusion 
method (10), averaged 90 %. Cells were then diluted 
with KRB to make a suspension of approximately 
3x106 hepatocytes per mL and incubated in sterile 
25 mL Erlenmeyer fl asks, each containing 3 mL of 
the cell suspension (i.e. 9x106 hepatocytes).
Incubation of hepatocytes
In order to choose appropriate amphetamine 
concentration for the in vitro  experiments, 
hepatocytes were incubated with D-amphetamine 
at four concentrations (50 µmol L-1, 100 µmol
L-1, 150 µmol L-1, and 200 µmol L-1) for one hour. 
Average toxic amphetamine concentration (TC
50
) 
was determined (Figure 1) to be 100 µmol L-1 
(TC
50
=1.05x10-4 mol L-1). Hepatocytes isolated from 
the animals of both groups were incubated with 
D-amphetamine at TC
50
 for one hour. Hepatocytes 
isolated from nifedipine-treated rats were pre-




 = 1.05 x 10-4 mol L-1












Vitcheva V, et al. ROLE OF CYP3A IN AMPHETAMINE HEPATOTOXICITY
Arh Hig Rada Toksikol 2009;60:139-145
141
incubated for 15 min with amiodarone (14 µmol L-1) 
(12) and then incubated for with D-amphetamine for 





 atmosphere (10). For both groups, non-treated 
hepatocytes were used as controls.
The following parameters were used to evaluate 
amphetamine cytotoxicity: cell viability, LDH activity, 
and GSH level. Cell viability was assessed using the 
Trypan blue exclusion method (10). The dye was used 
at the fi nal concentration of 0.05 %, and approx. 300 
cells were counted under a light microscope (x100). 
Cell samples were taken from each experimental 
group from three separate hepatocyte preparations at 
hour one of incubation. At the end of incubation, cells 
were recovered by centrifugation at 400xg at 4 °C. 
The supernatant was used for the assessment of LDH 
activity while the sediment to measure intracellular 
glutathione (GSH). The level of LDH activity was 
measured spectrophotometrically, as described by 
Bergmeyer et al. (13), using a commercially available 
kit (LDH opt., Randox). Briefl y, the method is based 
on the reduction of pyruvate to lactate. During 
the reduction, an equimolar amount of NADH is 
oxidised to NAD+, which leads to a decrease in 
the absorbance at 340 nm, measured at minute 1, 
2, and 3. The decrease in absorbance at 340 nm is 
directly proportional to LDH activity in the sample. 
LDH activity was calculated from the absorbance of 
NADH (6.22 mmol), and the fi nal results are given in 
mmol L-1 min-1 per 106 cells.
The GSH level was assessed by measuring non-
protein sulfhydryls after precipitation of proteins with 
trichloroacetic acid (TCA), followed by measurement 
of thiols in the supernatant using 2,2’-dinitro-
5,5’-dithiodibenzoic acid (DTNB) as reagent. The 
absorbance was measured at 412 nm (10), using a 
Spectro UV-VIS Split spectrophotometer, and the fi nal 
results are expressed in nmol per 106 cells.
Statistical analysis
Statistical analysis included ANOVA and the 
Student’s t-test. Probability values of less than 
0.05 were considered signifi cant. The results were 
presented as means ±SD of four animals per group. 
For each of the examined parameters, three parallel 
samples were used.
RESULTS
After one-hour of incubation in vitro, cell viability 
showed a slight, non-signifi cant decrease from the 
initial value (~90 %) to 85 % in the hepatocytes 
isolated from non-treated rats and to 78 % in the 
hepatocytes isolated from nifedipine-treated rats 
(Table 1). D-amphetamine administered in vitro at a 
concentration of 100 µmol L-1 affected cell viability, 
LDH activity, and GSH levels in hepatocytes isolated 
from non-treated and Nifedipine-treated rats. The 
incubation of hepatocytes isolated from non-treated 
rats with D-amphetamine led to a decrease in cell 
viability by 40 % (p<0.05), increased LDH leakage by 
184 % (p<0.05), and decreased level of cellular GSH 
by 54 % (p<0.05). Nifedipine treatment potentiated 
D-amphetamine cytotoxicity, and the most affected 
parameter was GSH level, followed by cell viability, 
and LDH activity. GSH was depleted by 80 % 
Table 1  The effect of D-amphetamine (100 µmol L-1) administered in vitro on cell viability, LDH activity, and GSH level in 






per 106 cells /
mmol L-1 min-1
GSH level
per 106 cells /
nmol
Non-treated rats
Control hepatocytes 85±3.2 0.131±0.01 19.14±1.93
Hepatocytes exposed in vitro to D-amphetamine 51±2.0* 0.372±0.07* 8.85±0.10*
Nifedipine-treated rats
Control hepatocytes 78±5.1 0.165±0.03 17.00±2.67
Hepatocytes exposed in vitro to D-amphetamine 26±1.5+# 0.479±0.03+# 3.40±0.40+#
Note. Data are expressed as mean ± SD of four different experiments.
*p<0.05 vs. LDH activity hepatocytes from non-treated rats
+p<0.05 vs. per 106 cells / hepatocytes from nifedipine-treated rats
#p<0.05 vs. mmol L-1min-1 hepatocytes from non-treated rats exposed to D-amphetamine
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(p<0.05) which is 62 % (p<0.05) more than the effect 
of D-amphetamine on hepatocytes isolated from non-
treated rats. Cell viability decreased by 67 % (p<0.05), 
which is 51 % (p<0.05) more than it was observed 
in amphetamine-treated hepatocytes isolated from 
non-treated rats. LDH activity increased by 190 % 
(p<0.05), which is commeasurable with the effect of 
amphetamine on cells isolated from non-treated rats.
Table 2 shows the influence of amiodarone 
(14 µmol L-1) on D-amphetamine effects in hepatocytes 
isolated from nifedipine-treated rats. Amiodarone 
itself exerted a hepatotoxic effect, manifested by a 
decrease in cell viability and GSH level by 35 % 
(p<0.05) and 50 % (p<0.05), respectively, and by an 
increase in LDH activity by 101 % (p<0.05). Pre-
incubation of hepatocytes with amiodarone resulted in 
lower cytotoxycity of D-amphetamine. Cell viability 
and the GSH level increased 22 % (p<0.05) and 79 % 
(p<0.05), respectively, while LDH activity decreased 
45 % (p<0.05) in respect to hepatocytes treated with 
D-amphetamine alone.
DISCUSSION
Amphetamines belong to a class of drugs 
known as central nervous system indirect-acting 
sympathomymetics, which are commonly abused 
due to their physical and psychostimulating effects. 
Sympathetic arousal induced by amphetamine produces 
rapid and sometimes irregular heart rate, sweating, 
papillary dilation, hypertension, and increased body 
temperature. The psychological changes include 
euphoria, alertness, hypervigilance, and decreased 
appetite. Beside the risk of developing tolerance and 
addiction, chronic abusers may experience neurotoxic 
effects (14) and hepatocellular damage (15). The latter 
has increasingly been reported in humans (16, 17).
In vitro studies in rats (4) have shown that 
amphetamine hepatotoxicity is closely related 
to its bioactivation and GSH-adduct (GSH-S-yl-
p-hydroxyamphetamine) formation, a process 
considered to be catalysed by CYP2D (4). Although 
the p-hydroxylation of amphetamine is considered 
to be the main metabolic pathway (1), it is possible 
that some other cytochrome P 450 dependent 
metabolic pathways be involved in its toxicity. There 
are clinical data revealing signifi cant interactions 
between recreational drugs, including amphetamine, 
and potent inhibitors of CYP3A4 such as some of the 
HIV protease inhibitors (18). Antiretroviral may cause 
fatal amphetamine accumulation from normally safe 
dosages, as they inhibit amphetamine metabolism. 
It is therefore possible that CYP3A was involved in 
amphetamine metabolism and toxicity in rats. 
L-type calcium channel blockers of the 
dihydropiridine class, such as nifedipine, nimodipine, 
and amlodipine have been reported to affect addiction 
to various types of drugs, including psychostimulants 
(19). At the same time, they are substrates of one of 
cytochrome P 450 most abundant isoenzyme CYP3A. 
Nifedipine is known to induce cytochrome P 450 both 
in rats (20) and humans (21).
To test the hypothesis of a possible involvement 
of CYP3A in amphetamine toxicity we used rat 
hepatocytes isolated from non-treated and nifedipine-







per 106 cells /
mmol L-1 min-1 
GSH level
per 106 cells /
nmol
Control hepatocytes isolated from nifedipine-induced 
rats
78±5.0 0.165±0.01 17.00±1.7
Hepatocytes exposed in vitro to amiodarone 
(14 µmol L-1)
51±7.0* 0.334±0.03* 8.42±1.3*
Hepatocytes exposed in vitro to D-amphetamine 
(100 µmol L-1)
36±2.0* 0.479±0.03* 4.50±0.4*
Hepatocytes exposed in vitro to D-amphetamine and 
amiodarone
44±1.5*+ 0.225±0.04+ 8.05±1.5*+
Note. Data are expressed as mean ± SD of four experiments
*p< 0.05 vs. control
+p<0.05 vs. hepatocytes treated only with D-amphetamine
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treated rats, which were then incubated with 
amphetamine. Our results showed that nifedipine 
increased amphetamine cytotoxicity.
Cell GSH was the most affected (Table 1) and 
its significant depletion is an interesting finding. 
It seems that CYP2D favours the formation of p-
hydroxyamphetamine, and CYP2D is known not 
to be inducible (22). The observed decrease in the 
hepatocyte GSH level caused by amphetamine in 
nifedipine-treated rats may therefore be a result of 
nifedipine induction of CYP3A. In addition, multiple 
nifedipine administration may induce several other 
CYP isoforms such as CYP2B and CYP2C (23). 
Literature data suggest that in addition to CYP2D, 
aromatic hydroxylation is catalysed by CYP2B (24), 
which can be induced by nifedipine, and therefore also 
responsible for the GSH depletion. This hypothesis, 
however, needs further investigations that are an object 
of future studies.
In order to clarify the role of nifedipine in 
amphetamine toxicity, hepatocytes isolated from 
nifedipine-treated rats were pretreated with 
amiodarone, a substrate and inhibitor of CYP3A (23; 
12). At a concentration of 14 µmol L-1 amiodarone 
decreased cell viability and GSH, and increased LDH 
activity (Table 2). Pre-incubation of hepatocytes with 
amiodarone signifi cantly reduced D-amphetamine 
cytotoxicity. The most indicative was the effect 
on the GSH level (Table 2). These results suggest 
that amiodarone may interfere with amphetamine 
metabolism by inhibiting amphetamine’s toxic 
metabolites to form. However, because amiodarone 
is metabolised by CYP3A, a competition between the 
two compounds is likely. To better understand this 
interaction, a more specifi c inhibitor should be used, 
such as ketoconazole. 
Using an inducer and inhibitor of CYP3A proved to 
be a reliable approach in elucidating the involvement 
of this isoform in amphetamine hepatotoxicity in 
isolated rat hepatocytes.
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Sažetak
ULOGA CYP3A-ENZIMA U TOKSIČNOSTI D-AMFETAMINA U SVJEŽE IZOLIRANIMA 
ŠTAKORSKIM HEPATOCITIMA
Cilj je ovoga istraživanja bio utvrditi toksičnost D-amfetamina u izoliranim štakorskim hepatocitima kako 
bi se razjasnila eventualna uloga enzima CYP3A u mehanizmu toksičnosti ovoga lijeka. U tu su svrhu 
mužjaci Wistar štakora pet dana primali nifedipin (5 mg kg-1 ip.), koji je supstrat i induktor CYP3A. Stanice 
izolirane iz jetre štakora koji su primali nifedipin i kontrolnih štakora inkubirane su s D-amfetaminom u 
njegovoj srednjoj toksičnoj koncentraciji (TC
50
) od 100 µmol L-1. Za procjenu eventualnoga toksičnoga 
djelovanja D-amfetamina na svježe izolirane hepatocite uporabili smo sljedeće parametre: preživljenje 
stanica te razine laktat dehidrogenaze (LDH) i glutationa (GSH). Rezultati su pokazali da je nifedipin 
pojačao toksično djelovanje amfetamina in vitro na sljedeći način: preživljenje stanica palo je za 65 % 
(p<0,001), GSH za 80 % (p<0,001), a razine LDH porasle su za 190 % (p<0.001). Radi pojašnjenja uloge 
nifedipina u citotoksičnosti amfetamina uporabili smo amiodaron, koji je supstrat i inhibitor CYP3A. 
Inkubacija hepatocita štakora koji su primali nifedipin s amiodaronom (14 µmol L-1) prije dodavanja 
amfetamina značajno je smanjila njegovu citotoksičnost. Ovi rezultati potvrđuju da D-amfetamin djeluje 
toksično na štakorske hepatocite te da u njegovome metabolizmu i toksičnome djelovanju na jetru sudjeluje 
CYP3A.
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